Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valery Polyakov

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Mini Reviews in Medicinal Chemistry|December 8, 2004
Decision support systems in drug discoveryJian Shen, Valery Polyakov, Ramesh Rachapudi, et al.
The Journal of Prosthetic Dentistry|July 31, 2024
Over 14-year survival of pressed e.max lithium disilicate glass-ceramic complete and partial coverage restorations in patients with severe wear: A prospective clinical studyMariam Margvelashvili-Malament, Van Thompson, Valery Polyakov, et al.
The Journal of Prosthetic Dentistry|September 18, 2022
Incidence of endodontic therapy after complete or partial coverage glass-ceramic restorations with a follow-up time of over 30 years: A prospective clinical studyKenneth A Malament, Mariam Margvelashvili-Malament, Zuhair S Natto, et al.
Journal of Chemical Information and Modeling|March 28, 2015
FOCUS--Development of a Global Communication and Modeling Platform for Applied and Computational Medicinal ChemistsNikolaus Stiefl, Peter Gedeck, Donovan Chin, et al.
Chemmedchem|July 10, 2018
X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid SyndromeJoerg Kallen, Christian Bergsdorf, Bertrand Arnaud, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Journal of Medicinal Chemistry|March 3, 2018
Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative BacteriaRobert J Moreau, Colin K Skepper, Brent A Appleton, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Journal of Medicinal Chemistry|April 30, 2021
Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive BacteriaGuillaume Lapointe, Colin K Skepper, Lauren M Holder, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Mini Reviews in Medicinal Chemistry|December 8, 2004
Decision support systems in drug discoveryJian Shen, Valery Polyakov, Ramesh Rachapudi, et al.
The Journal of Prosthetic Dentistry|July 31, 2024
Over 14-year survival of pressed e.max lithium disilicate glass-ceramic complete and partial coverage restorations in patients with severe wear: A prospective clinical studyMariam Margvelashvili-Malament, Van Thompson, Valery Polyakov, et al.
The Journal of Prosthetic Dentistry|September 18, 2022
Incidence of endodontic therapy after complete or partial coverage glass-ceramic restorations with a follow-up time of over 30 years: A prospective clinical studyKenneth A Malament, Mariam Margvelashvili-Malament, Zuhair S Natto, et al.
Journal of Chemical Information and Modeling|March 28, 2015
FOCUS--Development of a Global Communication and Modeling Platform for Applied and Computational Medicinal ChemistsNikolaus Stiefl, Peter Gedeck, Donovan Chin, et al.
Chemmedchem|July 10, 2018
X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid SyndromeJoerg Kallen, Christian Bergsdorf, Bertrand Arnaud, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Journal of Medicinal Chemistry|March 3, 2018
Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative BacteriaRobert J Moreau, Colin K Skepper, Brent A Appleton, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Journal of Medicinal Chemistry|April 30, 2021
Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive BacteriaGuillaume Lapointe, Colin K Skepper, Lauren M Holder, et al.
Pageof 1